A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors
| Autor: | Pedro Nazareth Aguiar, Mariane Teodoro Fernandes, Jacob J. Adashek, Ana Claudia Barbin Spinosa, Gilberto Lopes, Auro Del Giglio, Barbara de Souza Gutierres, Carmelia Maria Noia Barreto |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty medicine.medical_treatment Review Targeted therapy 03 medical and health sciences 0302 clinical medicine Breast cancer breast cancer Cyclin-dependent kinase Internal medicine medicine Adverse effect Pharmacology cyclin-dependent kinase 6 biology cyclin-dependent kinase 4 Cyclin-dependent kinase 4 business.industry endocrine therapy lcsh:RM1-950 Cancer General Medicine medicine.disease targeted therapy 030104 developmental biology lcsh:Therapeutics. Pharmacology Hormone receptor 030220 oncology & carcinogenesis biology.protein Molecular Medicine Cyclin-dependent kinase 6 business |
| Zdroj: | Drugs in Context, Vol 7, Pp 1-6 (2018) Drugs in Context |
| ISSN: | 1740-4398 |
| Popis: | In the last 3 years, a novel class of targeted therapy has been approved for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. There are currently three approved agents, which are oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. All of the approved drugs exhibit progression-free survival benefit when compared to standard of care and generally have less adverse events compared to traditional chemotherapeutic options. The treatment of HR+/HER2- advanced breast cancer is a continuously evolving landscape, and the addition of CDK4/6 inhibitors is the newest mechanism for treatment. In this review, we summarize all available data, highlight the unanswered questions, and discuss pharmacological differences between each CDK4/6 inhibitor. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|